The Future of Clinical Trials is Decentralised.
During the pandemic, decentralised clinical trials became more and more relevant. With moving away from on-site trials, this new trend changes the reality of big and complex data management, the use of artificial intelligence tools and new regulatory frameworks. How do we manage gathering, storage and processing of data in a decentralised environment? The community still discusses the full application of CTIS and the regulatory application.
At the Clinical Trials and Data Science Conference, decision-makers across the industry, regulatory and patient organisations will meet to discuss the future of clinical trials to find innovative solutions.
- Decentralised Clinical Trials
- Use of Data Science in Clinical Trials
- Updates on the EMA/HMA Big Data Taskforce
- DARWIN EU
- Data Protection and Security
- Artificial Intelligence Regulatory Frameworks: Impact on Pharma
- IMI Initiatives
- European Health Data Space (EHDS)
Why should you attend this conference?
Álmath Máire Spooner, PhD, RPh • Director of Regulatory Policy and Intelligence
Daniel Millar, MBA • Senior Director, Strategic Business Transformation
Janssen Research & Development, United States
Elke Stahl, PhD • Senior Expert, Clinical Trials Department
Federal Institute For Drugs and Medical Devices (BfArM), Germany
Jesper Kjær, MS • Co-Chair, EMA/HMA Big Data Steering Group; Director of Data Analytics Centre
Danish Medicines Agency (DKMA), Denmark
Patrick Brady, PharmD • Head Regulatory Policy & Intelligence
Bayer AG / Research & Development, Pharmaceuticals, Germany
Joyce Swart • Clinical Disclosure Lead
Alcon Research, LLC, United States
Nick Sykes, MS • Senior Director, Global Regulatory Affairs
Pfizer Inc, United Kingdom
Ruediger Pankow, DrSc • Principal Consultant, Regulatory Affairs
Parexel International, Germany
Fia Westerholm, DVM, MSc • Programme Assurance Manager
European Medicines Agency, Netherlands